Type 2 Diabetes Mellitus
📧 Sign up to get email alerts when something new happens for Type 2 Diabetes Mellitus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes [Phase 3]
Phase 3 trial updating efficacy and safety of vildagliptin vs placebo in adults with type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment [Phase 4]
A Phase 4 clinical trial evaluating the combination of dapagliflozin and saxagliptin added to basal-bolus insulin therapy in adults with Typ…
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Effects on Insulin Resistance With Tadalafil in Type 2 Diabetes - a Double-blind, Placebo-controlled Crossover Study [Phase 2]
A Phase 2 double-blind, placebo-controlled crossover trial assessing the effects of tadalafil on insulin resistance in adults with Type 2 di…
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan [Phase 4]
Phase 4 clinical trial update examining dose reduction and acute glycemic complications in people with type 2 diabetes who fast during Ramad…
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: Vitamin D, Insulin Resistance, and Cardiovascular Disease [NA]
Clinical trial update for a study on vitamin D, insulin resistance, and cardiovascular disease has completed with results posted in 2020.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-02-10Clinical Trial Update: Prognostic Predictors of Response to Hypoglycemic Therapy [Phase 4]
Phase 4 clinical trial update investigating predictors of response to hypoglycemic therapy in Type 2 diabetes.
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: The Cardiovascular and Renal Effects of Moringa Oleifera Extracts and Stevia Rebaudiana Bertoni in Patients With Type II Diabetes Mellitus [Phase 4]
Phase 4 trial update evaluating cardiovascular and renal effects of Moringa oleifera extracts and Stevia rebaudiana in patients with type 2 …
-
CLINICAL_TRIALS trial_result · 2020-02-05Clinical Trial Update: Short Term Effects of a Hibiscus Sabdariffa and Stevia Rebaudiana Drink on Cardiac Relaxation and Urinary Albumin Excretion in a Group of Diabetic Type 2 Subjects [Phase 4]
Phase 4 clinical trial evaluating short-term effects of a Hibiscus sabdariffa and Stevia rebaudiana drink on cardiac relaxation and urinary …
-
FDA approval · 2020-02-03FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for a dapagliflozin and metformin hydrochloride combination product from Prasco Laboratories. The pr…
-
EMA approval · 2020-01-31First oral GLP-1 treatment for type 2 diabetes
The EMA announces the first oral GLP-1 receptor agonist approved for type 2 diabetes, marking a new oral option in this drug class.
-
CLINICAL_TRIALS trial_result · 2020-01-31Clinical Trial Update: Medically Reproducing Bariatric Surgery [Phase 2]
A Phase 2 clinical trial update on a bariatric surgery approach for Type 2 Diabetes Mellitus has completed enrollment or study activities.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA) [Phase 3]
A Phase 3 clinical trial update on liraglutide in young adults with type 2 diabetes and cardiovascular disease has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan [Phase 4]
A Phase 4 trial comparing canagliflozin (Invokana) to standard dual therapy for type 2 diabetes during Ramadan has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: A Study to Evaluate Time in Range in Type 2 Diabetics Using Afrezza® Plus Basal Insulin Compared to Multiple Daily Injections [Phase 4]
Phase 4 trial evaluating time in range with Afrezza plus basal insulin versus multiple daily injections in Type 2 diabetes treated with insu…
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Trial for People With Established Type 2 Diabetes During Ramadan [Phase 4]
Phase 4 clinical trial update for people with established type 2 diabetes during Ramadan has completed.
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: SGLT-2 Inhibitor Empagliflozin Effects on Appetite and Weight Regulation. [Phase 4]
Phase 4 trial update examining empagliflozin effects on appetite and weight regulation in adults with type 2 diabetes.
-
CLINICAL_TRIALS research · 2020-01-28Clinical Trial Update: Effects of Mild Hypoglycaemia on Cognitive Function in Type 2 Diabetes [NA]
A completed clinical trial assessing how mild hypoglycemia affects cognitive function in individuals with type 2 diabetes.
-
FDA approval · 2020-01-27FDA Approved: TRIJARDY XR — Original Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
The FDA approved TRIJARDY XR, a fixed-dose combination tablet of empagliflozin, linagliptin, and metformin hydrochloride, in an original app…
-
FDA approval · 2020-01-27FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental NDA for INVOKAMET (canagliflozin and metformin hydrochloride) from Janssen Pharmaceuticals, Inc. This action con…
-
FDA label_change · 2020-01-27FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental labeling change for INVOKAMET XR, the fixed-dose combination of canagliflozin and metformin hydrochloride from J…
-
FDA approval · 2020-01-24FDA Approved: INVOKAMET XR — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVOKAMET XR, a fixed-dose combination of canagliflozin and metformin hydrochloride, submitted b…
-
FDA approval · 2020-01-24FDA Approved: INVOKAMET — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for INVOKAMET (canagliflozin and metformin hydrochloride) submitted by Janssen Pharmaceuticals, …
-
FDA approval · 2020-01-24FDA Approved: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for the dapagliflozin and metformin hydrochloride combination product submitted by Prasco Labora…
-
FDA approval · 2020-01-24FDA Approved: GLYXAMBI — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for GLYXAMBI (empagliflozin and linagliptin) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.
-
FDA label_change · 2020-01-24FDA Approved: STEGLUJAN — Supplemental Application (Merck Sharp & Dohme LLC)
FDA overview of a supplemental application for Steglujan (ertugliflozin and sitagliptin) from Merck Sharp & Dohme LLC.